Healthcare Royalty Partners
includes HealthCare Royalty Partners III
8 statements across 1 episodes · 1 bullish · 0 bearish · 1 people on the record · first statement Jun 1, 2020 by Clark Futch · said 7 times in 1 episodes since 2020 · across every show →
Mentions by year, the whole family
brought up most by Ted Seides (4), Clark Futch (3)
tap a year for its mentions
2020 7 mentions in 1 episode
Everything said about Healthcare Royalty Partners, oldest first
Jun 1, 2020 bullish
Futch: Royalty monetization transaction volume grew from $150M to $9B
“The first year I was there, I think the total amount of transaction volume of all deals added up together for the whole year was like one hundred fifty million dollars. So really, really small. It's subsequently grown last year's about nine billion dollars of …”
Jun 1, 2020
Jun 1, 2020
Futch: Healthcare royalty diligence eliminates binary risks to focus on commercial risk
“Those three risks, the patents, manufacturing, and regulatory, are really what we view as potential binary risk. So if the product For safety reasons, gets pulled from the market because it's, have some significant side effect. That's a problem for us because …”
Jun 1, 2020 neutral
Futch: Biopharma equity raises two to five times more than royalty markets
“If you look at primarily equity raised, either venture capital raised or IPOs or following equity, it's a small fraction. There's two, three, four, five times as much money raised in the equity markets each year, but the equity markets can be volatile, right?”
Jun 1, 2020 neutral
Jun 1, 2020
Futch: HCR structures pre-approval deals in one-third and two-thirds tranches
“So we may put a portion, maybe a third of the capital in Six months before approval, three months before approval, and then have it set up that when it's approved, the second tranche, the post-approval tranche with two-thirds of the capital goes in.”
Jun 1, 2020 neutral